Teva Gets What It Wants

Recs

2

Teva Pharmaceutical (Nasdaq: TEVA) investors got a welcome surprise on Friday when a court ordered the FDA to award the company a 180-day exclusive selling period for its generic version of Johnson & Johnson's (NYSE: JNJ) Risperdal tablets.

Teva had sued for the exclusivity period because it filed its Abbreviated New Drug Application with the FDA, claiming that a Johnson & Johnson patent was invalid. The agency apparently agreed with Teva, because it removed the patent from its book of patents, but never awarded Teva the exclusivity period.

According to IMS Health data cited by Teva, Risperdal had U.S. sales of about $2.5 billion last year. If Teva can capture just 25% of the market and price the drug at 90% of Johnson & Johnson's price, it'll bring in more than $230 million during its six months of exclusive sales. Not a bad boost for a company that raked in $9.4 billion in revenue last year, especially considering that its generic Risperdal will fetch much higher gross margins than its drugs that have competition.

Ironically, the court's decision could actually help Johnson & Johnson. The drugmaker might see fewer patients switching to generics, since there will be only one high-priced generic on the market. Mylan (NYSE: MYL), Par Pharmaceutical (NYSE: PRX), and Barr Labs (NYSE: BRL), among others, already have tentative FDA approval to market their liquid and tablet version of the drug.

I wouldn't be shocked if the FDA appealed the decision. The agency turned down Teva's Citizen's petition to reinstate the patent, which started the legal battle, so the agency clearly thinks it had the right not to award the exclusivity period. The most recent legal battle took about a month to sort out, so an appeal might be decided before Risperdal goes off patent in June.

It's hard to tell how this one will eventually end up, but the most recent decision should give investors confidence in Teva's legal team -- a nice thing to have in an industry where companies live and die by their court decisions.

Closed for 15 months – opening 10 days only! Get notified ahead of time as our expert portfolio manager invests $1 MILLION in the best opportunities from across The Motley Fool’s premium investment services. This is the first open since August 2008, by invitation only. Enter email below.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 620720, ~/Articles/ArticleHandler.aspx, 11/9/2009 11:51:53 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

The Must-Read Story on Fool.com
Health-Care Reform: A Tale of Two Chambers

Related Tickers

12/22/2008 4:02 PM
BRL $65.80 Down +0.00 +0.00%
Barr Pharmaceutica… CAPS Rating: ****
JNJ $60.75 Up +0.45 +0.75%
Johnson & Johnson CAPS Rating: *****
PRX $22.00 Down +0.00 +0.00%
Par Pharmaceutical… CAPS Rating: ***
MYL $17.91 Up +0.44 +2.52%
Mylan Laboratories… CAPS Rating: ***
TEVA $53.20 Up +1.17 +2.25%
Teva Pharmaceutica… CAPS Rating: *****

Community: Investing Wiki

Term Of The Hour

Variable cost: A variable cost is an expense that rises or falls in conjunction with a company's level of productivity.

Want to learn more or edit this definition?
Click here to read more!